Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoronaVac + BBIBP-CorV + Convidecia
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoronaVac + BBIBP-CorV + Convidecia refers to a heterologous vaccination regimen against COVID-19, utilizing a combination of inactivated and viral vector vaccine technologies. CoronaVac (developed by Sinovac) and BBIBP-CorV (developed by Sinopharm) are inactivated vaccines that use a chemically weakened version of the SARS-CoV-2 virus to stimulate an immune response. Convidecia (developed by CanSino Biologics) is a viral vector vaccine that uses a modified adenovirus type 5 (Ad5) to deliver the genetic code for the SARS-CoV-2 spike protein. This combination is primarily employed in heterologous prime-boost schedules, where individuals initially vaccinated with inactivated vaccines receive the viral vector vaccine as a booster to enhance neutralizing antibody titers and cellular immunity against SARS-CoV-2 variants.
- Brand names
- Hayat-Vax
- Other names
- Sinovac vaccineSinopharm vaccineCanSino vaccinePakVac
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CoronaVac + BBIBP-CorV + Convidecia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoronaVac + BBIBP-CorV + Convidecia.